Board of Advisors
Our Board of Advisors, all industry leaders, have made a powerful statement by supporting Life Science Cares and our goal to end poverty in our community. Annually, our Advisors make a personal financial contribution to cover LSC’s administrative costs, allowing us to channel money raised from our event fundraisers, Corporate Membership Program, and from individuals to our partner organizations.
Our Board of Advisor members also choose to volunteer with their companies and recruit their colleagues to join in this collective effort. For more information on how to join our Board of Advisors please email [email protected]
SAN DIEGO BOARD OF ADVISORS
ABCDEFGHIJKLMNOPQRSTUVWXYZ
Chuck Baum
President, Founder and Head of Research & Development, and Board Member
Mirati Therapeutics
Chuck Baum
President, Founder and Head of Research & Development, and Board Member – Mirati TherapeuticsPresident and Chief Executive Officer
Chuck Baum, M.D., Ph.D.
Amy Bergen
Vice President, Business Development – The Leadership Edge
Sarah Bhagat
Biotech Investor
Sarah Bhagat
Biotech Investor
Greg Bisconti
Vice Chairman, National Life Science Practice Lead – Cushman & Wakefield
Tasia Blazevich
Managing Director – Deloitte
Sarah Boyce
President & CEO – Avidity Biosciences
Vika Brough
Chief Accounting Officer – Mirador Therapeutics
Dan Burgess
Venture Partner – SV Health Investors
James Burns
Chief Executive Officer – Locana bio
Ousmane Caba
Partner – PwC
Jeremy Caldwell, PhD
Partner – Red Tree Venture Capital
Cris Calsada
Chief Financial Officer – Regulus Therapeutics
Travis Carter
President – Carter+Co
Joseph Castagnola
Managing Director, Private Wealth Advisor – Morgan Stanley
Jacob Chacko
CEO – ORIC PharmaceuticalsCEO
ORIC Pharmaceuticals
Isan Chen M.D.
President & CEO – MBrace Therapeutics, Inc.
James Christensen
Chief Scientific Officer – Bristol Squibb
Tom Coll
Partner – Cooley
Dee Dee DeMan
Chairman & CEO – Bench International
Karen Deschaine
Partner – Wilson Sonsini Goodrich & Rosati
Michael Dudley
President and Chief Executive Officer – QPEX BIOPHARMA
Laure Escoubet
Senior Vice President, Head of Research – Light Horse Therapeutics
Dan Estes, Ph.D
General Partner – Frazier Life Sciences
Daniel Faga
Chief Executive Officer – AnaptysBio
Kevin Finney
Chairman & CEO – Autobahn Therapeutics, Inc
Robert Gaan
Chief Investor Relations Officer – Christopher Weil & Company, Inc
Jennifer Giottonini Cayer
Chief Business Officer – Pulmocide
David Hale
Hale BioPharrmaVentures
David Hale
Hale BioPharrmaVentures
Todd Harris
Founder & CEO – Tyra Biosciences
Gerry Hernandez
SVP, Head of Finance – Vividion
Jackie Hernandez, CPA
Founder – Hernandez & Co. Consulting
Zachary Hornby
President & CEO – Boundless Bio, Inc.
Fleming Jones
Managing Director – FlemingMartin Executive Search
David Kabakoff
Executive Partner Private Equity – SOFINNOVA Investments
Ida Khodami
Partner – Two Bear Capital
Craig Knox
Vice Chairman, Western Region Life Science Co-Lead – Savills North America
Neha Krishnamohan
Chief Financial Officer & EVP, Corporate Development – Artiva Biotherapeutics
Ajay Kshatriya
CEO – Aizen Therapeutics
Cathy Lee
EVP, General Counsel and Corporate Secretary – Metacrine
Hugh Leslie
Principal, Life Science & Technology Practice Lead – Marsh McLennan Agency
Alyssa Levin
Chief Financial Officer & Business Officer – Nkarta
Stanley Lewis M.D., M.P.H.
Founder and CEO – A288 Therapeutics
Adam Lohr
Partner, and West Coast Life Science Leader – RSM US LLP
Erik Lundh
Co-Founder and Managing Partner – Park Square Executive Search
James Mackay, Ph.D.
President & CEO – Aristea Therapeutics
Mason Matthies
Managing Director – Donnelley Financial Solutions
Damien McDevitt, PhD
President & CEO – Aspen Neuroscience, Inc
Emily McDonald
Managing Director – KPMG
Alana McNulty
Director – Janux Therapeutics
Shelly Meeusen
Chief Science Officer – Velia
Mike Milligan
Managing Director – C3 Risk & Insurance
Hala Mirza
Senior Vice President, Corporate Affairs – Ionis Pharmaceuticals
Scott Moorefield
COO/CBO – Alterome Therapeutics
Bob More
Alta Partners
Bob More
Alta Partners
Eric Murphy, Ph.D
Co-Founder, CEO & CSO – Alterome Therapeutics
Joe Panetta
President & CEO – Biocom California
Joseph Payne
Founder, President & CEO – Arcturus Therapeutics
Lina Pitesa Waage
President, Board of Directors – JDRF San Diego Chapter
Bill Rastetter
Chairman – Fate TherapeuticsChairman, Fate
Chairman, Neurocrine
Chairman, Daré
Vickie Reed
Board Member and Audit Chair; Chief Accounting Officer (retired)
Mirati Therapeutics (retired)
Vickie Reed
Board Member and Audit Chair; Chief Accounting Officer (retired) – Mirati Therapeutics (retired)
Mark Rothera
President & CEO – Viracta Therapeutics
Daniel Ryan
Co-Chief Investment Officer & Regional Market DirectorSan Diego Alexandria Real Estate Equities
San Diego Alexandria Real Estate Equities
Daniel Ryan
Co-Chief Investment Officer & Regional Market DirectorSan Diego Alexandria Real Estate Equities – San Diego Alexandria Real Estate Equities
Josh Schimmer
Managing Director, Biotechnology Equity Research – Cantor Fitzgerald
Dan Schroeder
Managing Director – First Republic Bank, San Diego
Linda Sierra
SVP, Business Development – Bench International
Jodi Smith-Ungrodt
Partner – EY
Randy Socol
Partner – DLA Piper
Bruce Steel
Chief Executive Officer – Equillium
Laurie Stelzer
Chief Financial Officer – Mirati Therapeutics
Jason Stewart
Founder & CEO – Blake & Michaels
America Thompson
Vice President, Finance & Accounting – Kate Therapeutics
Stacey Tyree
Principal – RE:Align Tenant Strategies
Esther van den Boom
Managing Partner – van den Boom & Associates
Ashley Van Zeeland, PhD, MBA
Vice President, Corporate & Business Development – Illumina
Roberto Vieira
President, Oncology – Corcept Therapeutics
Christian Waage
Executive Vice President – Gossamer Bio
Lisa Walters-Hoffert
Chief Financial Officer – Daré Bioscience
Mark Wiggins
Chief Business Officer – Vaxcyte
Troy Wilson
President & CEO – Kura Oncology
Holly Winter
Senior Vice President Human Resources – Locanabio, Inc.
Ian Wisenberg
Chief Executive Officer – BioCina
Thomas Woiwode, PhD
Managing Director – Versant Ventures